Price T Rowe Associates Inc Centessa Pharmaceuticals PLC Call Options Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CNTA
# of Institutions
73Shares Held
84.5MCall Options Held
17.7KPut Options Held
5K-
Medicxi Ventures Management (Jersey) LTD20MShares$174 Million59.15% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$87.1 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$84.6 Million2.56% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.62MShares$49.1 Million1.81% of portfolio
-
Vida Ventures Advisors, LLC3.93MShares$34.4 Million65.7% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $825M
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...